ArticleExperimental and therapeutic medicine2026
Gastric wall thickening and gastric outlet obstruction due to peritoneal metastasis in breast cancer: A case report.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal metastasis from breast cancer is rare and diagnostically challenging. This challenge is particularly compounded in patients receiving CDK4/6 inhibitors, as their characteristic gastrointestinal adverse effects can mimic the symptoms of peritoneal carcinomatosis. A woman with hormone receptor-positive/HER2-negative metastatic breast cancer developed symptoms of functional gastric outlet obstruction (manifesting as delayed gastric emptying) 2 months after initiating palbociclib treatment. Imaging revealed diffuse and marked gastric wall thickening. Initial gastroscopic biopsies were non-diagnostic, but laparotomy confirmed peritoneal carcinomatosis, with histology and immunohistochemistry confirming metastatic breast cancer. The present case underscores the diagnostic difficulty in differentiating drug toxicity from disease progression in patients on CDK4/6 inhibitors. The key clinical messages are: i) Persistent gastrointestinal symptoms despite CDK4/6 inhibitor withdrawal warrant investigation for peritoneal metastasis; ii) serosal-based metastases have the potential to cause notable gastric wall thickening and functional gastric outlet obstruction while sparing the mucosa, potentially evading initial endoscopic diagnosis; and iii) a multifactorial pathogenesis involving structural infiltration and neuro-myogenic dysfunction is proposed to underlie this clinical presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.